source
- STAT+: ‘Synthetic lethality’ could trigger another round of biotech M&AProving out a "synthetic lethality" approach can help treat cancer will take a lot more work. It also might trigger some creative deal-making.STAT · 1mo ago↗ source
- HHS responds coolly to paper on alcohol riskSoda and liver cancer, scientists conflicted on a new NIH proposal, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testThe results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.BioPharma Dive · 1mo ago↗ source